@article{032d3e59e2c04e07a029b9a81fd4ee4d,
title = "Investigational antiviral drugs for the treatment of COVID-19",
abstract = "A large number of candidate drugs are undergoing evaluation for their potential to limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. Clinical trial data are slowly emerging for several of these agents. We provide a review of candidate antiviral agents registered in ClinicalTrials.gov, which have clinical efficacy data, provide the rationale for their consideration for this purpose, and summarize available data on their efficacy and safety.",
keywords = "COVID-19, Camostat, DAS-181, Favipiravir, Hydroxychloroquine, Ivermectin, Lopinavir/ritonavir, Nafamostat, Nitazoxanide, Remdesivir, Ribavirin, SARS-CoV-2, Umifenovir",
author = "Vegivinti, {C. T.R.} and M. Assi and R. Talwani and V. Koblizek and K. Burke and Zelalem Temesgen",
note = "Funding Information: Several trials have evaluated the safety and efficacy of remdesivir for the treatment of COVID-19. These include randomized controlled investigator-initiated studies, case series and expanded access studies, as well as studies sponsored by the manufacturer of remdesivir, the National Institutes of Health (NIH), and the World Health Organization (WHO) (7, 8). A meta-analysis of remdesivir clinical trials was inconclusive regarding the efficacy of remdesivir in treating COVID-19 due to the heterogeneity of the design and reporting of the studies as well as the low quality of the evidence (9). A living systematic review and network meta-analysis that compared the effects of investigational drug treatments for COVID-19 was recently updated (10). Studies of interest were randomized clinical trials in which people with suspected or confirmed COVID-19 were randomized to drug treatment or to standard care or placebo. The data sources consisted of the following: WHO COVID-19 database, a comprehensive multilingual source of global COVID-19 literature, which merged with the U.S. Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database in October 2020; and 6 additional Chinese databases. Eighty-five trials enrolling over 41,000 patients met the inclusion criteria for analysis. Publisher Copyright: {\textcopyright} 2021 Clarivate Analytics",
year = "2021",
month = sep,
doi = "10.1358/dof.2021.46.9.3293585",
language = "English (US)",
volume = "46",
pages = "697--710",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "9",
}